MediciNova, Inc. Stock price
Is MediciNova, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
MediciNova, Inc. Stock Analysis
Analyst Opinions
9 Analysts have issued a MediciNova, Inc. forecast:
Analyst Opinions
9 Analysts have issued a MediciNova, Inc. forecast:
Don't miss a Thing! We will send you all news about MediciNova, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MediciNova, Inc. Stock News
Company Profile
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
| Head office | United States |
| CEO | Dr. Iwaki |
| Employees | 6 |
| Founded | 2000 |
| Website | medicinova.com |


